Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dronedarone→

Dronedarone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
141626-36-0
Molecular formula
C31H44N2O5S
Molecular weight
556.8 g/mol
Drug class
Multichannel antiarrhythmicclass III-like rhythm-control agent
Mechanism of action
Inhibits multiple ion channels, including potassium, sodium and calcium currents, and has antiadrenergic effects, prolonging cardiac action potential and refractoriness while slowing conduction.
Indications / reported uses
  • Reduction of risk of hospitalisation for atrial fibrillation in adults with a history of paroxysmal or persistent atrial fibrillation who are in sinus rhythm or will be cardioverted; contraindicated in permanent AF and certain heart failure settings

Sources: US DailyMed — MULTAQ (dronedarone) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Dronedarone Environmental Risk Assessment (ERA) (the Dronedarone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.